Table 3. Clinical characteristics of all individuals included in the analysis to investigate future coronary artery disease events (CAD; n = 4543) and divided by incidence coronary artery disease events (inc. CAD).
| Complete n = 4543 | No CAD n = 3895 |
Inc. CAD n = 648 |
P value | |
|---|---|---|---|---|
| Current smokers, n (%) | 980 (22) | 815 (21) | 165 (25) | 0.009 |
| Male sex, n (%) | 1763 (39) | 1395 (36) | 368 (57) | <0.001 |
| Age (years), median (IQR) | 57.7 (52.2–62.6) | 57.2 (52.0–62.3) | 60.2 (54.6–63.8) | <0.001 |
| Prevalent diabetes, n (%) | 364 (8) | 272 (7) | 92 (14) | <0.001 |
| Hypertension, n (%) | 1604 (35) | 1303 (33) | 301 (46) | <0.001 |
| Lipid-lowering treatment, n (%) | 77 (2) | 57 (1) | 20 (3) | 0.007 |
| CRP (mg/L), median (IQR) | 1.3 (0.7–2.7) | 1.3 (0.6–2.6) | 1.7 (0.8–3.5) | <0.001 |
| HbA1c %, median (IQR) | 4.8 (4.5–5.1) | 4.8 (4.5–5.1) | 4.9 (4.6–5.2) | <0.001 |
| Fasting lipoproteins (mmol/L) | ||||
| Cholesterol, median (IQR) | 6.1 (5.4–6.8) | 6.1 (5.4–6.8) | 6.3 (5.6–7.0) | <0.001 |
| LDL, median (IQR) | 4.1 (3.5–4.8) | 4.1 (3.5–4.7) | 4.4 (3.7–5.0) | <0.001 |
| HDL, median (IQR) | 1.4 (1.1–1.6) | 1.4 (1.2–1.6) | 1.2 (1.0–1.5) | <0.001 |
| TG, median (IQR) | 1.1 (0.9–1.6) | 1.1 (0.9–1.6) | 1.3 (1.0–1.7) | <0.001 |
| Fasting glucose, mmol/L (IQR) | 4.9 (4.6–5.3) | 4.9 (4.6–5.2) | 5.0 (4.7–5.4) | <0.001 |
Hypertension was defined as blood pressure >159/94 mmHg or antihypertensive treatment. CRP, C-reactive protein. HbA1c, haemoglobin A1c. LDL, low-density lipoprotein. HDL, high-density lipoprotein. TG, triglyceride. P value describes the significant difference comparing individuals with or without coronary artery disease (CAD) during follow-up. The number of individual data for each variable was as follows: Smoking, n = 4536; CRP, n = 4442; HbA1c, n = 4543; total cholesterol, n = 4541, LDL, n = 4537, HDL, n = 4542; and triglycerides, n = 4542.